Resume
Summary Research Q8 - Infectious Diseases
- Cours
- Établissement
(Extended) Summary Research Q8 - Infectious Diseases, including lectures and self study assignments for each lecture.
[Montrer plus]
3 revues
Par: marasnaa • 3 année de cela
Par: leonieengel7 • 4 année de cela
Par: michellec2000 • 4 année de cela
Vendeur
S'abonner
rdeveer
Avis reçus
Aperçu du contenu
Renske de Veer (rdeveer)Summary Infectious diseases and global health
HC 1: Clinical presentation, biology, and treatment
HIV is a RNA retrovirus infecting CD4 T-cells in the blood: RNA is transcriptased into cDNA. cDNA is
integrated into our genome.
- Reverse transcriptase: virus brings this enzyme to make cDNA from RNA.
- Integrase: integrating piece of cDNA into our genome stimulating it to produce new virus
particles.
- Protease: necessary for viral assembly.
Viral replication of HIV
3 enzymes:
• Reverse transcriptase: enzyme that the virus
brings and makes C DNA from RNA.
• Integrase: integrating that piece of DNA into
the genome → transcribe it to new HIV-RNA
particles.
• Protease: enzymes needed in the final step.
Virus uses specific cellular receptors → CD4 most
important. CD4 mainly expressed on T lymphocytes.
The second receptors → chemokine co-receptors
(to get into the cell):
• CCR 5 (early in infection)
• CYCR 4 (later in infection)
You will need both receptors to get the infection.
HIV infects and destroys CD 4 cells. Only 1% of CD4 cells are in the blood. Loss of CD4+ memory T-
cells decrease ‘cellular immunity’ and predisposes to certain infections and malignancies.
CD4 also on other cells: megakaryocytes, glial cells in the brain
Durable (natural) control of HIV
,Renske de Veer (rdeveer)
- Higher viral setpoint: faster CD4 cell decline
- Preferential (irreversible) loss of certain T-cell populations (specific CD4 cells (specific
recognize tb cells) → early/more loss)
o Especially gut Th17 cells (translocation/immune activation)
The earlier we treat → the more we can preserve the immune system → the more we limit the viral
reservoir : goes to brain, intestine, prostate, etc → earlier to treat the better.
1. Primary HIV
o Usually 2-4 weeks after infection
o Flu-like syndrome
▪ Fever, lymphadenopathy, pharyngitis, rash, meningoencephalitis
o Laboratory
▪ Mononucleosis (atypical lymphocytes)
▪ High plasma HIV-RNA
▪ Incomplete antibody response
▪ Temporary drop in CD4
2. Progressive CD4 cell loss
o People become susceptible to opportunistic infections.
3. Besides infections and AIDS
o Cardiovascular disease
o ‘Normal’ malignancies
o Allergy and autoimmune disease
o Rapid ‘aging’ and many organ systems
▪ Liver, kidney, brain, lungs, bone
o Patients liver longer: chronic disease
Natural course of disease after infection is variable
- Acute HIV (viral syndrome)
- Many patients with asymptomatic infection
- Opportunistic infections & malignancies (AIDS)
- Antiretroviral treatment (ART)
- Targets for treatment
o The 3 important enzymes (RT inhibitors
+ protease inhibitor → fusion
inhibitors)
o Entry blockers: block the binding to the
co-receptor
,Renske de Veer (rdeveer)
- When to use it:
o For AIDS-symptomatic patients
o To prevent AIDS
o To prevent transmission
o To slow ‘chronic HIV’
- Problems with ART
o Safety (drug allergy)
o Side effect
▪ Protease inhibitors: diarrhea
▪ Neurocognitive & psychiatric side effects
▪ Anemia, nausea
▪ Muscle pain
o Long-term toxicity:
▪ Mitochondrial toxicity
• Associated with all the drugs
• Screen for hyperlactatemia
• Lipodystrophy
▪ Pancreatitis
▪ Kidney stones
▪ Insulin resistance
▪ Cariomyopathy
▪ Osteoporosis
▪ Kidney function
▪ etc
o Adherence
o Resistance
o Drug-drug interactions: cytochromes (inducer/inhibitor)
o ‘Immune reconstitution’
HIV as a chronic disease
- Phenotype is changing
- Cardiovascular disease, diabetes, malignancies, liver disease, kidney function loss, cognitive
function, depression, substance abuse, co-infections, ‘frailty’.
, Renske de Veer (rdeveer)
HC 2: Disease heterogeneity
Many disease have typical disease presentation & disease course.
Knowing a disease is relevant to know which treatment to give, and provides a prognosis.
➔ A diagnosis informs how treatment will change natural course.
Diseases show heterogeneity in
- Onset (why one person gets a disease/diagnosis and why another doesn’t)
- Symptoms
- Natural progression
- Treatment response and outcomes
Heterogeneity can be caused by:
- Disease
o Time of diagnosis (misdiagnosis)
▪ Distribution of all people (e.g. older people) → people who are in the lower
bit of the curve (below the average) → combination of people who are in the
pre-stage and people who don’t have the disease (mixed group) →
heterogeneity in the progression. (misdiagnosis of people that are not really
in the pre-stage)
o Nosological variants
▪ Some diseases have a group of symptoms that don’t say much about the
course itself (dementia: syndrome, not a disease → many common types). →
different course underlying the disease.
▪ Early and late form (onset) of a disease (dementia: people diagnosis on early
age and later age; family in which everyone gets alzheimer’s disease. People
with early from tend to progress much faster).
o Disease severity
▪ People with a lower CD4 have the chance of HIV but also for HAND
- Patient (More than 75% of all older people have more than 2 (or more) disease).
o Comorbidity: presence of one or more additional diseases or disorders co-occuring
with a primary disease or disorder. Usually people with higher comorbidity progress
faster compared to people with lower comorbidity.
o Frailty (vulnerability)
▪ A patient changes when time goes on en becomes more/less frail, get
more/less comorbidity which may in/decrease in severity.
▪ Frailty measures state, no performance
o Resilience (resilience of people and how they deal with health)
▪ The ability to bounce back when being perturbated by health stressors: how
does one response.
• Resistance
• Recovery
• Adaptability
- Care
o Quality of Care
- Wider context: environmental factors/social life/etc
o Informal caregiver
▪ Social relationship determine a better prognosis
o Social functioning
▪ Better quality of life results in a lower mortality risk
Les avantages d'acheter des résumés chez Stuvia:
Qualité garantie par les avis des clients
Les clients de Stuvia ont évalués plus de 700 000 résumés. C'est comme ça que vous savez que vous achetez les meilleurs documents.
L’achat facile et rapide
Vous pouvez payer rapidement avec iDeal, carte de crédit ou Stuvia-crédit pour les résumés. Il n'y a pas d'adhésion nécessaire.
Focus sur l’essentiel
Vos camarades écrivent eux-mêmes les notes d’étude, c’est pourquoi les documents sont toujours fiables et à jour. Cela garantit que vous arrivez rapidement au coeur du matériel.
Foire aux questions
Qu'est-ce que j'obtiens en achetant ce document ?
Vous obtenez un PDF, disponible immédiatement après votre achat. Le document acheté est accessible à tout moment, n'importe où et indéfiniment via votre profil.
Garantie de remboursement : comment ça marche ?
Notre garantie de satisfaction garantit que vous trouverez toujours un document d'étude qui vous convient. Vous remplissez un formulaire et notre équipe du service client s'occupe du reste.
Auprès de qui est-ce que j'achète ce résumé ?
Stuvia est une place de marché. Alors, vous n'achetez donc pas ce document chez nous, mais auprès du vendeur rdeveer. Stuvia facilite les paiements au vendeur.
Est-ce que j'aurai un abonnement?
Non, vous n'achetez ce résumé que pour 3,99 €. Vous n'êtes lié à rien après votre achat.
Peut-on faire confiance à Stuvia ?
4.6 étoiles sur Google & Trustpilot (+1000 avis)
76669 résumés ont été vendus ces 30 derniers jours
Fondée en 2010, la référence pour acheter des résumés depuis déjà 14 ans